COVID Testing Kit Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global COVID Testing Kit Market Trends and Insights

High Incidence of COVID-19 Variants

The virus’s evolution toward seasonal patterns similar to influenza reduces the urgency for mass testing but preserves baseline surveillance requirements. The WHO’s advisory group now focuses on XBB-lineage strains, signaling a move to vaccinate and monitor rather than broadly screen entire populations.^{[1]World Health Organization, “Technical Advisory Group on COVID-19 Vaccine Composition,” who.int} Labcorp reported a sequential fall in COVID testing revenue of 1.9% in Q1 2024 and 0.9% in Q2 2024, a pattern echoed across major laboratories as acute-phase demand subsides. Diagnostic companies must therefore balance lower volumes with the need to maintain sequencing capacity for variant detection. Platform flexibility and integrated data reporting become important differentiators as health agencies continue to rely on laboratories for genomic surveillance. Manufacturers that embed variant-specific primers into existing assays can capture ongoing institutional demand without incurring the cost of new kit development. 

Expanding Governmental Stockpiling Programs

Government preparedness initiatives create a demand floor even as private-sector ordering wanes. The U.S. Department of Health and Human Services has invested more than USD 3 billion to maintain domestic rapid test production and procured 500 million at-home tests for strategic reserves.^{[2]U.S. Department of Health & Human Services, “Rapid Test Procurement Contracts,” hhs.gov} Similar procurement frameworks in the European Union guarantee manufacturers multi-year purchase commitments, offsetting margin erosion in retail channels. By stabilizing baseline production, these contracts help suppliers retain skilled labor and sustain quality systems required under ISO 13485 and FDA Quality System Regulation. In return, governments gain assured surge capacity for future outbreaks, supporting broader national security goals. 

Rapid Consumer Shift to Self-Testing

Saliva-based diagnostics that users can collect at home reach 97.8% detection rates when processed with optimized bead-mill homogenizers, closely matching laboratory-collected nasopharyngeal swabs.^{[3]Brian Labus, “Self-Collected Saliva Shows High Sensitivity for SARS-CoV-2,” Science Daily, sciencedaily.com} At-home sampling eliminates healthcare-worker exposure and reduces personal protective equipment use, lowering overall system costs. Digital apps that interpret line-intensity and transmit results to public-health dashboards further strengthen adoption in North America and Europe. Integration with telehealth services allows physicians to issue antiviral prescriptions and isolation guidance within minutes, transforming a single-use test into a gateway for virtual care. Kit makers that package intuitive instructions, companion apps, and multilingual support see higher repeat purchase rates, particularly among elderly and pediatric populations. 

Commercialization of CRISPR-Based Diagnostics

CRISPR-Cas systems coupled with isothermal amplification now deliver results in nearly real time. Mammoth Biosciences’ DETECTR BOOST kit processes roughly 1,500 samples per eight-hour shift while bypassing supply-chain constraints associated with conventional enzymes. Columbia Engineering researchers have demonstrated a plasmonic nanoparticle RT-PCR platform that cuts turnaround time to 23 minutes without sacrificing sensitivity. Such innovations are crucial for emergency-department triage and for airports aiming to reopen international travel with minimal delays. While regulatory pathways remain complex, early-adopting hospitals that run CRISPR-based assays alongside traditional RT-PCR are reporting workflow efficiencies and lower reagent costs. 

Declining Test Volumes as Pandemic Subsides

Diagnostic companies have reported 70-90% drops in COVID test orders compared with peak 2021 levels. Abbott cut 199 jobs at its Maine facility, and Cue Health reduced headcount by 170 as public funding pivoted toward vaccines and therapeutics. Fixed manufacturing overhead now spreads across smaller batches, intensifying cost pressures. Laboratories are rationalizing inventories, carrying just-in-time stocks rather than months of safety supplies. In this environment, suppliers are shuttering satellite plants, automating packaging lines, and renegotiating raw-material contracts to align capacity with new baseline demand. 

Price Commoditization Squeezing Margins

Emergency premium pricing has evaporated, placing commodity-level price caps on most antigen and RT-PCR kits. Major diagnostics firms disclosed sharp revenue declines linked to COVID testing: DiaSorin –13.7%, Quest Diagnostics –6.4%, Danaher –11.7%, and Abbott –39.4% year-on-year in 2024 earnings reports. Competitive tenders from pharmacies and online retailers now favor low-cost suppliers, compressing gross margins. To protect profitability, manufacturers are expanding value-added services such as digital result archiving, workplace screening programs, and assay customization for combined respiratory panels. Those unable to bundle software, analytics, or multi-pathogen capability risk competing purely on price, triggering further consolidation. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Innovation Offsets Volume Decline

RT-PCR assay kits sustained their lead with 73.42% COVID testing kit market share in 2025 as hospitals and reference labs trust their accuracy for regulatory and reimbursement compliance. However, the CRISPR-based molecular subgroup is projected to log the highest 1.90% CAGR through 2031, reflecting laboratory demand for rapid, point-of-care workflows. Immunoassay cassettes capture mass-screening orders yet face margin erosion, while next-generation sequencing panels remain confined to variant surveillance programs. Multiplex respiratory assays that detect SARS-CoV-2, influenza A/B, and RSV in a single run clock in at 97-100% accuracy with sub-hour turnaround, a capability that supports their premium pricing. 

The segment reveals a split between commodity tests and higher-value specialized diagnostics. Companies that deploy modular cartridge systems can swap reagents to meet seasonal pathogen patterns, thereby shielding revenue. Columbia Engineering’s 23-minute RT-PCR prototype hints at future benchmarks for emergency-department throughput. Simultaneously, CRISPR assays that distinguish active viral replication from residual fragments could guide quarantine decisions and antiviral prescriptions, carving out clinical niches even as total test numbers fall. Suppliers that merge these technical advances with automated result reporting stand to capture enduring demand in a downsized yet technology-savvy marketplace. 

By Specimen: Self-Collection Redefines Preferences

Nasopharyngeal swabs continue to hold 58.35% of 2025 revenue owing to long-standing clinical validation, but saliva collection is on track for a 2.08% CAGR to 2031 as consumers demand non-invasive options. Studies report 97.8% viral detection in saliva processed with bead-mill homogenizers, far exceeding the 78.9% achieved by nasopharyngeal swabs under standard lab conditions. Nasal swabs offer a compromise between comfort and accuracy, whereas oropharyngeal sampling remains protocol-driven for certain hospital settings. Finger-prick blood tests continue to serve antibody surveillance rather than acute diagnosis. 

Self-collection changes logistics, shifting kit distribution from hospital supply chains to retail and e-commerce outlets. Digital apps guide users through collection, reducing indeterminate results and boosting consumer confidence. Public-health agencies gain timely data when apps push anonymized positives to epidemiological dashboards, aligning specimen innovation with surveillance objectives. Manufacturers are enhancing stabilizing buffers to extend sample viability during shipment, opening avenues for mail-in laboratory PCR services that circumvent cold-chain requirements. 

By End User: Households Emerge as Growth Engine

Diagnostic laboratories accounted for 55.60% of 2025 revenue, leveraging automated sample handling and consolidated purchasing. Home care settings, however, are forecast to expand at a 2.18% CAGR through 2031 as consumers normalize routine self-testing before travel, family gatherings, or work. Hospitals retain acute-care testing yet increasingly rely on in-house panels that bundle COVID with other respiratory pathogens to justify operational costs. Public-health agencies now focus on sentinel surveillance rather than universal testing, purchasing kits in bulk for targeted community programs. 

Expansion in the home segment reflects broader decentralization in healthcare delivery. PLoS ONE studies show self-collected swabs achieving 99% gonorrhea detection accuracy, reinforcing consumer trust in self-sampling across disease states. Kit makers capitalize by offering family-size packs and subscription models with telemedicine consults, lifting lifetime customer value beyond a single diagnostic sale. Platforms that combine Bluetooth-enabled readers with cloud dashboards enable physicians to monitor patient status, aligning kit sales with long-term digital-health revenue. 

Geography Analysis

North America retained its leading 39.30% slice of the COVID testing kit market in 2025, buffered by USD 3 billion in federal funding for rapid-test procurement and manufacturing resilience. Yet commercial volumes shrank sharply after insurers curtailed blanket coverage, prompting manufacturers to streamline plants and prioritize higher-margin multiplex panels. Abbott Laboratories disclosed that lower COVID testing revenue and export tariffs will trim more than USD 1 billion from 2025 sales, illustrating the pressure on incumbents. FDA rulemaking on laboratory-developed-test oversight introduces new validation costs but promises a harmonized pathway for rapid approvals, benefitting firms that can meet stringent performance benchmarks. 

Asia-Pacific recorded the fastest regional expansion at a 1.98% CAGR and is expected to keep that momentum through 2031 as urban hospitals prioritize combined respiratory panels to manage overlapping flu and COVID seasons. Governments are channeling recovery funds into molecular-diagnostic capacity, including subsidies for domestic reagent manufacturing. Public-private partnerships in India and China are building centralized data platforms that connect test readers to cloud analytics, transforming discrete kits into surveillance assets for health ministries. Nevertheless, uneven insurance coverage and variable reimbursement slow widespread adoption outside tier-one cities. 

Europe continues to emphasize institutional purchasing, guided by the European Medicines Agency’s collaboration on global vaccine and diagnostic standards. Health systems are adding sustainability clauses to contracts, rewarding vendors that use recyclable plastics or supply take-back services. This environmental focus raises cost-of-goods for some suppliers but differentiates early movers in public tenders. In Latin America and Africa, donor-funded initiatives are improving laboratory networks, yet budget constraints keep average selling prices below global norms. Suppliers addressing these regions tailor stripped-down kits that retain core sensitivity while accommodating hot-chain shipping and minimal instrumentation. 

Regulatory Landscape

COVID-19 testing kits operate under a mix of emergency and conventional regulatory pathways, with regulators tightening long-term requirements for performance, quality systems, and post-market oversight. In the United States, the FDA continues to maintain EUAs for in vitro diagnostics and publishes dedicated policies and FAQs for SARS-CoV-2 testing and OTC home diagnostics, while the Federal Register (September 23, 2025) finalized FDA guidance on enforcement policies for IVD tests during a Section 564 declared emergency. That clarification specifies the criteria for when unapproved tests may be offered during future declared emergencies.

In Europe, implementation of the In Vitro Diagnostic Regulation (IVDR) continues to reshape market access for SARS-CoV-2 tests through transitional timelines and reclassification impacts. Regulation (EU) 2024/1860, in force from July 9, 2024, extended transition periods for legacy IVDs to reduce supply disruption. Updated European Commission and MDCG-aligned classification guidance for SARS-CoV-2 tests also tightened expectations for higher-risk classifications, raising the bar for notified-body engagement, quality management system alignment (commonly ISO 13485), and conformity assessment planning, particularly for products migrating into higher classes with nearer-term submission deadlines.

Market Opportunities and Future Outlook

An opportunity is emerging around test formats and workflows aligned to routine respiratory-virus surveillance and care pathways, rather than mass one-pathogen screening. Government procurement and preparedness programs provide demand anchors for manufacturers that can supply compliant, scalable products. The US Department of Health and Human Services has invested more than USD 3 billion to sustain domestic rapid test production and has procured 500 million at-home tests for strategic reserves, helping suppliers maintain validated production lines and quality systems as commercial volumes normalize.

Regulatory normalization also creates room for companies transitioning portfolios from EUA to traditional authorization, with differentiation increasingly tied to multiplexing and connectivity. In June 2026, the FDA classified a simple point-of-care device to directly detect SARS-CoV-2 into class II with special controls (21 CFR 866.3982), reinforcing a clearer long-term pathway for point-of-care COVID tests and supporting investment in cleared product lines rather than emergency-only offerings. On the public-health side, multi-pathogen surveillance and sentinel approaches continue to expand, including wastewater-based monitoring. In 2026, Australia launched a three-year National Wastewater Surveillance Program across 47 sentinel sites, pointing to ongoing institutional spend on SARS-CoV-2 monitoring infrastructure that complements clinical testing and supports demand for high-throughput molecular platforms and integrated reporting.